NBE-Therapeutics had presented at BioEquity Conference Europe

Ulf Grawunder presented preclinical data of NBE's first lead ADC candidates NBE-001 and NBE-002 for multiple myeloma and breast cancer

NBE-Therapeutics has been invited as a presenting company in the "Next Wave Companies" session at the 17th BioEquity Europe conference in Copenhagen, Denmark. The conference took place from May 10-11, 2016, and had a record attendance of over 500 delegates from the Life-Science and Investment community. Ulf Grawunder, CEO of NBE-Therapeutics, provided an overview about the development activities of NBE-Therapeutics focused on preclincal and clinical validation of the company's first ADC lead development candidates in the indications Multiple Myeloma and breast cancer.